Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN67,3867,430,60
Msft-0,25
Nokia3,653,68951,33
IBM2,53
Mercedes-Benz Group AG64,764,721,22
PFE0,91
13.07.2024 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 12.07.2024 16:59:57
Bavarian Nordic (BAVA.CO, Copenhagen)
Závěr k 12.7.2024 Změna (%) Změna (DKK) Objem obchodů (DKK)
177,85 -1,55 -2,80 44 940 328
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.07.2024
Popis společnosti
Obecné informace
Název společnostiBavarian Nordic A/S
TickerBAVA
Kmenové akcie:Ordinary Shares
RICBAVA.CO
ISINDK0015998017
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.03.2024
Počet zaměstnanců k 31.03.2024 1 381
Akcie v oběhu k 23.05.2024 78 072 582
MěnaDKK
Kontaktní informace
UlicePhilip Heymans Alle 3
MěstoHELLERUP
PSČ2900
ZeměDenmark
Kontatní osobaRolf Soerensen
Funkce kontaktní osobyVice President, Investor Relations and Communications
Kontatní telefon4 533 268 383

Business Summary: Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in manufacturing of pharmaceutical preparations. The Company is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The Company deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The Company operates worldwide.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Bavarian Nordic A/S revenues decreased 34% to DKR831.5M. Net loss totaled DKR114.5M vs. income of DKR376.4M. Revenues reflect Sale of goods - MVA-BN smallpox vaccine sale segment decrease of 59% to DKR343.8M, Sale of goods - other product sale segment decrease of 25% to DKR32.3M. Net loss reflects Administrative increase of 33% to DKR120.3M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Research and Development in Biotechnology
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 14.07.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive OfficerPaul Chaplin5728.05.2014
Deputy Chairman of the BoardAnders Pedersen7301.01.2022
Executive Vice President, Chief Financial OfficerHenrik Juuel5901.11.201801.11.2018
Executive Vice President, Chief Operating OfficerRussell Thirsk5601.04.202201.04.2022
Executive Vice President - People and OrganizationAnu Kerns52
Executive Vice President, Chief Commercial OfficerJean-Christophe May57